30,000 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by Connective Portfolio Management LLC
30,000 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by Connective Portfolio Management LLC
Connective Portfolio Management LLC acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 30,000 shares of the biotechnology company's stock, valued at approximately $331,000.
根據Connective Portfolio Management LLC最近提交給美國證券交易委員會的文件,該公司在第二季度收購了Iovance BioTreateutics,Inc.(納斯達克代碼:IOVA-GET Rating)的一個新頭寸。該機構投資者購買了30,000股這家生物技術公司的股票,價值約331,000美元。
Several other hedge funds and other institutional investors have also modified their holdings of IOVA. Raymond James & Associates boosted its position in shares of Iovance Biotherapeutics by 21.8% during the fourth quarter. Raymond James & Associates now owns 10,036 shares of the biotechnology company's stock worth $192,000 after buying an additional 1,797 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Iovance Biotherapeutics by 167.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 884,481 shares of the biotechnology company's stock worth $16,886,000 after buying an additional 553,559 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Iovance Biotherapeutics by 24.7% during the fourth quarter. Teacher Retirement System of Texas now owns 23,627 shares of the biotechnology company's stock worth $451,000 after buying an additional 4,681 shares during the period. Rhumbline Advisers boosted its position in shares of Iovance Biotherapeutics by 3.5% during the fourth quarter. Rhumbline Advisers now owns 134,519 shares of the biotechnology company's stock worth $2,568,000 after buying an additional 4,603 shares during the period. Finally, Bank of Montreal Can purchased a new position in Iovance Biotherapeutics in the fourth quarter valued at $2,510,000.
其他幾家對衝基金和其他機構投資者也調整了對IOVA的持股。Raymond James&Associates在第四季度將其在Iovance BioTreateutics的股票頭寸提高了21.8%。Raymond James&Associates現在持有這家生物技術公司10,036股股票,價值192,000美元,在此期間又購買了1,797股。Dimension Fund Advisors LP在第四季度將其在Iovance BioTreateutics的股票頭寸增加了167.3%。Dimension Fund Advisors LP現在擁有884,481股這家生物技術公司的股票,價值16,886,000美元,在此期間又購買了553,559股。德克薩斯州的教師退休系統在第四季度將其在Iovance BioTreateutics的股票的頭寸提高了24.7%。德克薩斯州教師退休系統公司現在持有這家生物技術公司的23,627股票,價值451,000美元,在此期間又購買了4,681股票。Rhumbline Advisers在第四季度將其在Iovance BioTreateutics的股票頭寸增加了3.5%。在此期間,Rhumbline Advisers又購買了4,603股,現在擁有134,519股這家生物技術公司的股票,價值2,568,000美元。最後,蒙特利爾銀行可以在第四季度購買Iovance BioTreateutics的一個新頭寸,價值251萬美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
IOVA has been the subject of a number of recent research reports. The Goldman Sachs Group decreased their target price on Iovance Biotherapeutics from $64.00 to $18.00 and set a "buy" rating for the company in a report on Friday, July 1st. Chardan Capital cut their price target on Iovance Biotherapeutics from $31.00 to $30.00 in a research note on Friday, August 5th. JMP Securities restated a "buy" rating and issued a $25.00 price target on shares of Iovance Biotherapeutics in a research note on Monday, September 12th. Truist Financial cut their target price on Iovance Biotherapeutics to $18.00 in a research report on Tuesday, August 23rd. Finally, Robert W. Baird cut their target price on Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating on the stock in a research report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $23.80.
IOVA是最近一些研究報告的主題。在7月1日星期五的一份報告中,高盛夫婦將他們對Iovance BioTreateutics的目標價從64.00美元下調至18.00美元,並對該公司設定了“買入”評級。8月5日,Chardan Capital在一份研究報告中將Iovance BioTreateutics的目標價從31.00美元下調至30.00美元。JMP證券公司在9月12日星期一的一份研究報告中重申了買入評級,併發布了Iovance BioTreateutics股票的目標價25.00美元。Truist Financial在8月23日週二的一份研究報告中將其對Iovance BioTreateutics的目標價下調至18.00美元。最後,羅伯特·W·貝爾德在8月5日的一份研究報告中將其對Iovance BioTreateutics的目標價從34.00美元下調至25.00美元,並對該股設定了“跑贏大盤”的評級。一名股票研究分析師對該股的評級為賣出,兩名分析師對該股給予持有評級,八名分析師對該公司給予買入評級。根據MarketBeat的數據,該股的共識評級為“適度買入”,共識目標價為23.80美元。
Iovance Biotherapeutics Price Performance
Iovance生物療法的性價比
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same quarter in the prior year, the firm earned ($0.53) earnings per share. Research analysts anticipate that Iovance Biotherapeutics, Inc. will post -2.53 earnings per share for the current year.
IOVance BioTreateutics(納斯達克代碼:IOVA-GET Rating)最近一次公佈季度收益數據是在8月4日星期四。這家生物技術公司公佈的季度每股收益為0.63美元,低於分析師普遍預期的0.60美元和0.03美元。去年同期,該公司每股收益為0.53美元。研究分析師預計,Iovance BioTreateutics,Inc.本年度每股收益將達到2.53美元。
Iovance Biotherapeutics Profile
Iovance生物療法簡介
(Get Rating)
(獲取評級)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Iovance BioTreateutics,Inc.是一家臨牀階段的生物技術公司,專注於開發癌症免疫治療產品並將其商業化,以利用患者免疫系統的力量根除癌細胞。該公司正在進行6項第二階段臨牀研究,包括其主要候選產品lifileucel的C-144-01,用於治療轉移性黑色素瘤;C-145-04,其候選產品lifileucel,用於復發、轉移或持續性宮頸癌;以及C-145-03,其候選產品LN-145,用於治療復發和/或轉移性頭頸部鱗狀細胞癌。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 免費獲取StockNews.com關於Iovance生物療法(IOVA)的研究報告
- 華爾街對Datadog的熱情會帶來巨大的收益嗎?
- MarketBeat:回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性?
- 需要關注的2只半導體類股走勢逆轉
- 小盤股的裁員是樓市的晴雨表嗎?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《愛的生物療法日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Iovance BioTreateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。